SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Dollars as a global currency, loan, credit, and payment concept. A hand offering 100 US dollars. Minimalist art collage
ADCs
Don’t Call It a Crossover, but Alentis Raises $181M Series D for ADC Work
CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But Alentis is targeting an IPO as early as 2025.
November 12, 2024
 · 
2 min read
 · 
Annalee Armstrong
Illustration of hand holding trophy with people coming out of trophy and celebrating
Job Trends
BioSpace Announces 2025 Best Places to Work in Biopharma
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
November 12, 2024
 · 
6 min read
 · 
Angela Gabriel
Brain shaped maze. Concept image of study and brain behavior.
Schizophrenia
AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, which put the drug at the center of expectations.
November 11, 2024
 · 
4 min read
 · 
Annalee Armstrong
Pictured: Novavax/Getty Images, STR/NurPhoto
FDA
UPDATE: FDA Lifts Clinical Hold on Novavax’s COVID/Flu Vaccine Candidates, Clears Phase III Trial
Novavax’s shared jumped 12% in pre-market trading on the news.
November 11, 2024
 · 
2 min read
 · 
Annalee Armstrong
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Pipeline
RAPT Crashes After Axing Atopic Dermatitis, Asthma Hopeful, Cites Liver Injury
In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.
November 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Rhinosinusitis, sinusitis concept image
Immunology and inflammation
AstraZeneca, Amgen Claim Late-Stage Win in Chronic Rhinosinusitis but Analyst Flags ‘Regulatory Risk’
The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not expect the antibody to outperform Dupixent.
November 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: GSK's headquarters in London
Policy
GSK Quits Trade Group BIO as Industry Faces Uncertain Political Future
GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug price negotiation program.
November 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Neurons sending pulsating electric impulses and communicating with each other. Concept For Neurological Diseases, Tumors And Brain Surgery
Huntington’s
5 Huntington’s Therapies to Watch
A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win. Here, BioSpace looks at five candidates that could change the trajectory for patients.
November 11, 2024
 · 
5 min read
 · 
Kate Goodwin
Madrid, Spain cityscape at Calle de Alcala and Gran Via.
Alzheimer’s
Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s Disease conference focused on the role these drugs might play, as well as combination therapies and innovative new treatment options.
November 11, 2024
 · 
6 min read
 · 
Kate Goodwin
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS